119 related articles for article (PubMed ID: 23765241)
1. Duck HBV DNA copy numbers in isolated hepatocyte nuclei vary dramatically and decline during entecavir therapy.
Shen G; Fu X; Zhou B; Yin J; Zhong C; Chen J; Hou J
Antivir Ther; 2013; 18(8):987-96. PubMed ID: 23765241
[TBL] [Abstract][Full Text] [Related]
2. Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection.
Miller DS; Boyle D; Feng F; Reaiche GY; Kotlarski I; Colonno R; Jilbert AR
Virology; 2008 Apr; 373(2):329-41. PubMed ID: 18206204
[TBL] [Abstract][Full Text] [Related]
3. Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.
Foster WK; Miller DS; Scougall CA; Kotlarski I; Colonno RJ; Jilbert AR
J Virol; 2005 May; 79(9):5819-32. PubMed ID: 15827196
[TBL] [Abstract][Full Text] [Related]
4. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis.
Reaiche GY; Le Mire MF; Mason WS; Jilbert AR
Virology; 2010 Oct; 406(2):286-92. PubMed ID: 20705309
[TBL] [Abstract][Full Text] [Related]
5. Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver.
Reaiche-Miller GY; Thorpe M; Low HC; Qiao Q; Scougall CA; Mason WS; Litwin S; Jilbert AR
Virology; 2013 Nov; 446(1-2):357-64. PubMed ID: 24074600
[TBL] [Abstract][Full Text] [Related]
6. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
[TBL] [Abstract][Full Text] [Related]
7. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication.
Marion PL; Salazar FH; Winters MA; Colonno RJ
Antimicrob Agents Chemother; 2002 Jan; 46(1):82-8. PubMed ID: 11751115
[TBL] [Abstract][Full Text] [Related]
8. Alternative methods for validation of cell culture infection with duck hepatitis B virus.
Sauerbrei A; Schacke M; Schultz U; Egerer R; Merkle I; Glebe D; Gerlich W; Wutzler P
J Virol Methods; 2005 Nov; 129(2):178-85. PubMed ID: 16002155
[TBL] [Abstract][Full Text] [Related]
9. Antiviral effects of PNA in duck hepatitis B virus infection model.
Chen ZY; Cheng AC; Wang MS; Xu DW; Zeng W; Li Z
Acta Pharmacol Sin; 2007 Oct; 28(10):1652-8. PubMed ID: 17883953
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: one virus DNA genome is infectious in neonatal ducks.
Jilbert AR; Miller DS; Scougall CA; Turnbull H; Burrell CJ
Virology; 1996 Dec; 226(2):338-45. PubMed ID: 8955053
[TBL] [Abstract][Full Text] [Related]
11. Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.
Foster WK; Miller DS; Marion PL; Colonno RJ; Kotlarski I; Jilbert AR
Antimicrob Agents Chemother; 2003 Aug; 47(8):2624-35. PubMed ID: 12878529
[TBL] [Abstract][Full Text] [Related]
12. Development and application of a universal Taqman real-time PCR for quantitation of duck hepatitis B virus DNA.
Wang Y; Li Y; Yang C; Hui L; Han Q; Ma L; Wang Q; Yang G; Liu Z
J Virol Methods; 2013 Jul; 191(1):41-7. PubMed ID: 23557670
[TBL] [Abstract][Full Text] [Related]
13. [Study on the replication of hepatitis B virus compared with that of duck hepatitis B virus in primary duck hepatocytes].
Yao Y; Tang N; Huang A
Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1157-61. PubMed ID: 11769700
[TBL] [Abstract][Full Text] [Related]
14. [Anti-virus effect of hepatocyte stimulating substance (HSS) on duck hepatitis B virus in vivo].
Chen G; Chen J; Liu D; Zhang X; Zhu C; Li Y; Wang L; Yang Y; Cai G; Han F
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Dec; 11(4):329-32. PubMed ID: 15617240
[TBL] [Abstract][Full Text] [Related]
15. The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines.
Feng F; Teoh CQ; Qiao Q; Boyle D; Jilbert AR
Vaccine; 2010 Oct; 28(46):7436-43. PubMed ID: 20833122
[TBL] [Abstract][Full Text] [Related]
16. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
[TBL] [Abstract][Full Text] [Related]
17. Effects of liver growth factors on hepadnavirus replication in chronically infected duck hepatocytes.
Schorr O; Borel C; Trepo C; Zoulim F; Hantz O
J Hepatol; 2006 May; 44(5):842-7. PubMed ID: 16458387
[TBL] [Abstract][Full Text] [Related]
18. Efficient inhibition of duck hepatitis B virus DNA by the CRISPR/Cas9 system.
Zheng Q; Bai L; Zheng S; Liu M; Zhang J; Wang T; Xu Z; Chen Y; Li J; Duan Z
Mol Med Rep; 2017 Nov; 16(5):7199-7204. PubMed ID: 28944845
[TBL] [Abstract][Full Text] [Related]
19. 2',3'-dideoxy-3'-fluoroguanosine inhibits duck hepatitis B virus in vivo.
Löfgren B; Vickery K; Zhang YY; Nordenfelt E
J Viral Hepat; 1996 Mar; 3(2):61-5. PubMed ID: 8811639
[TBL] [Abstract][Full Text] [Related]
20. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks.
Fourel I; Cullen JM; Saputelli J; Aldrich CE; Schaffer P; Averett DR; Pugh J; Mason WS
J Virol; 1994 Dec; 68(12):8321-30. PubMed ID: 7966625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
